Hoey Paris, Roche Douglas, Chapman Paul, Kaushik Vishal, Llewellyn Stacey, Adris Niwansa
Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
Intern Med J. 2025 Jan;55(1):89-100. doi: 10.1111/imj.16541. Epub 2024 Nov 7.
Central line-associated bloodstream infections (CLABSIs) are a potential complication for home parenteral nutrition (HPN) patients.
We sought to analyse risk factors of developing HPN-related CLABSI and assess CLABSI management in the Australian context.
A retrospective observational cohort study was conducted on 34 adult patients receiving HPN via a central venous catheter (CVC) at a Queensland tertiary referral centre between 2016 and 2023. Patient charts were reviewed, and Kaplan-Meier analysis was employed to determine associations between characteristics and time to CLABSI in the first CVC using Peto-Peto Prentice test.
A total of 39 CLABSI episodes occurred in 19 patients. Patients with ≥1 CLABSI used regular opioids more than those without CLABSI (P = 0.016). Fourteen (41%, n = 14/34) patients developed a CLABSI in their first CVC. No patient or line characteristics were found to be predictive of CLABSI in their first CVC. The CLABSI rate was 1.02/1000 catheter days. Most CLABSIs were caused by Enterobacterales (22%, n = 12/55) and Candida sp. (22%, n = 12/55). Empiric antimicrobial therapy was adequate in only 25% (n = 7/28), and the median time to effective antibiotic therapy was 22.7 h (interquartile range 4.8-29.8). There were three successful CVC salvages (8%, n = 3/39).
In this cohort of patients, regular opioid use was associated with increased risk of developing CLABSI. Based on our findings, an empiric antimicrobial regime of vancomycin, cefepime and caspofungin will provide adequate coverage for most HPN-related CLABSIs in Australian IF units with a similar antimicrobial distribution and resistance pattern.
中心静脉导管相关血流感染(CLABSI)是家庭肠外营养(HPN)患者的一种潜在并发症。
我们试图分析发生HPN相关CLABSI的危险因素,并评估澳大利亚背景下CLABSI的管理情况。
对2016年至2023年期间在昆士兰一家三级转诊中心通过中心静脉导管(CVC)接受HPN的34例成年患者进行了一项回顾性观察队列研究。查阅患者病历,并采用Kaplan-Meier分析,使用Peto-Peto Prentice检验确定特征与首次CVC发生CLABSI时间之间的关联。
19例患者共发生39次CLABSI发作。发生≥1次CLABSI的患者比未发生CLABSI的患者更常使用常规阿片类药物(P = 0.016)。14例(41%,n = 14/34)患者在其首次CVC时发生了CLABSI。未发现患者或导管特征可预测其首次CVC发生CLABSI。CLABSI发生率为1.02/1000导管日。大多数CLABSI由肠杆菌科细菌(22%,n = 12/55)和念珠菌属(22%,n = 12/55)引起。经验性抗菌治疗仅有25%(n = 7/28)足够,有效抗生素治疗的中位时间为22.7小时(四分位间距4.8 - 29.8)。有3次成功挽救CVC(8%,n = 3/39)。
在该队列患者中,常规使用阿片类药物与发生CLABSI的风险增加相关。根据我们的研究结果,对于澳大利亚具有相似抗菌药物分布和耐药模式的IF单位,万古霉素、头孢吡肟和卡泊芬净的经验性抗菌方案将为大多数HPN相关CLABSI提供足够的覆盖。